CVT 313

Drug Profile

CVT 313

Latest Information Update: 16 Jul 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CV Therapeutics
  • Developer CV Therapeutics; Nonindustrial source
  • Class Small molecules
  • Mechanism of Action Cyclin-dependent kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Coronary artery restenosis; Vascular restenosis

Most Recent Events

  • 14 Apr 2000 New profile
  • 14 Apr 2000 Preclinical development for Coronary artery restenosis in USA (Unknown route)
  • 14 Apr 2000 Preclinical development for Vascular restenosis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top